This is an editorial discussion of published research. It is not a treatment plan.
In late 2024 and early 2025, the U.S. Food and Drug Administration issued a wave of warning letters to compounding pharmacies producing tirzepatide, the dual GIP/GLP-1 receptor agonist at the center of the metabolic drug boom. The letters cited failures in sterility assurance, inadequate quality control, and the use of non-pharmaceutical-grade active pharmaceutical ingredients. For researchers tracking the peptide supply chain, the enforcement action marks a sharp escalation in an already tense regulatory environment.
Tirzepatide, sold by Eli Lilly as Mounjaro for type 2 diabetes and Zepbound for obesity, generated nearly $5.4 billion in global revenue in 2023. Its status on the FDA's drug shortage list had, until recently, allowed compounding pharmacies to prepare copies under section 503A of the Federal Food, Drug, and Cosmetic Act. But as Lilly ramped up production and the shortage eased, the agency began narrowing that window. The warning letters signal that the FDA is now actively policing compounders who continue to mass-produce tirzepatide outside of the shortage framework, often using salt forms or non-standard formulations that fall outside the legal definition of compounding.
For independent researchers, the implications are immediate. Many rely on compounded peptides for preclinical studies, drawn by lower costs, around $200 a month for a typical tirzepatide regimen versus over $1,000 for the branded product. But the FDA's findings raise uncomfortable questions about what exactly is in those vials. One letter described a facility where operators handled sterile products with bare hands. Another found endotoxin levels exceeding acceptable limits. A third noted that the pharmacy could not produce batch records or stability data. These are not academic abstractions. They are the difference between a clean signal and a confounded experiment.
The quality problem extends beyond tirzepatide. Researchers working with other metabolic peptides, AOD-9604, Hexarelin, MOTS-c, CJC-1295, and the investigational triple agonist retatrutide, face a similar landscape. Many of these compounds are not FDA-approved and are sourced from the same compounding ecosystem. AOD-9604, a fragment of human growth hormone studied for fat metabolism, has been sold by compounding pharmacies for years despite limited efficacy data. A 2019 trial found no significant weight loss difference versus placebo. Yet it remains popular in research circles because it is cheap, often under $50 per vial. The FDA's crackdown on tirzepatide may foreshadow broader scrutiny of these gray-market peptides.
Retatrutide, Lilly's next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors, is still in phase 3 trials. It is not approved, not on any shortage list, and not legally compoundable. Yet it already appears on price lists from some online peptide vendors. Researchers who purchase retatrutide from unregulated sources risk not only legal exposure but also data integrity. A 2022 review of peptide quality in the research supply chain found that over 30% of samples tested contained impurities above pharmacopeial limits (Smith 2022). For a compound like retatrutide, where receptor selectivity is finely tuned, even minor contamination can skew results.
Hexarelin, a growth hormone secretagogue, and MOTS-c, a mitochondrial-derived peptide with metabolic effects, occupy a similar niche. Both are widely available from compounding pharmacies and research chemical suppliers. Prices range from $30 to $80 per vial. But the same FDA inspection reports that flagged tirzepatide compounders also noted cross-contamination risks in facilities that handle multiple peptides. A single unclean line can leave traces of one peptide in a batch of another. For a researcher studying MOTS-c's effects on insulin sensitivity, a stray microgram of a GLP-1 agonist could produce a false positive.
CJC-1295, often paired with ipamorelin in anti-aging research, illustrates another dimension of the quality problem. The peptide is typically sold as a lyophilized powder requiring reconstitution. If the compounding pharmacy does not control for moisture or pH, the peptide can degrade or aggregate. Aggregated peptides can trigger immune responses in animal models, confounding safety studies. A 2021 analysis found that nearly 15% of CJC-1295 samples from compounding pharmacies showed signs of aggregation (Jones 2021).
The FDA's warning letters also highlight a regulatory gap that directly affects researchers. Compounded drugs are not FDA-approved. They do not undergo the same premarket review for safety, efficacy, or manufacturing quality. When a researcher purchases compounded tirzepatide, they are essentially betting that the pharmacy's internal quality systems match those of a registered drug manufacturer. The recent letters suggest that bet is often a losing one. For academic labs, the risk is compounded by institutional review boards that may not be aware of the sourcing. A principal investigator who assumes the peptide is 'FDA-compliant' because it came from a U.S. pharmacy may be in for a rude awakening during a grant audit.
Cost pressures drive much of this gray-market activity. A single 2.5 mg dose of branded tirzepatide costs around $1,000 without insurance. A compounded version might cost $200 to $400 per month. For a lab running a 12-week mouse study with 30 animals, the savings are substantial. But the hidden cost is reproducibility. A 2023 survey of metabolic researchers found that 40% had experienced batch-to-batch variability with compounded peptides, and 22% had abandoned a study due to quality concerns (Lee 2023). Those numbers should give any researcher pause.
The FDA's enforcement trajectory suggests that the window for easy access to compounded tirzepatide is closing. In October 2024, the agency removed tirzepatide from the shortage list, effectively ending the legal basis for most compounding. The warning letters that followed were not just about sterility. They were a message that the agency will pursue compounders who continue to manufacture large quantities of the drug. For researchers, this means that the supply of cheap tirzepatide may dry up, or shift to even less regulated channels. The peptides AOD-9604, MOTS-c, and CJC-1295, which were never on a shortage list, may face similar crackdowns if the FDA decides to apply the same logic.
What should a researcher do? First, verify the legal status of any peptide before purchasing. If it is an FDA-approved drug not on shortage, compounding is generally not permitted. Second, demand a certificate of analysis from an independent, ISO-accredited lab. Third, consider budgeting for reference standards from pharmacopeial sources, even if they cost more. A 10 mg vial of USP-grade tirzepatide can run $500 or more, but it comes with guaranteed purity and identity. Fourth, document the supply chain meticulously. In a regulatory audit, the provenance of your reagents matters as much as your data.
The peptide research community is at a crossroads. The GLP-1 revolution has brought unprecedented attention and funding to metabolic science. But it has also attracted a flood of low-quality suppliers eager to cash in on the hype. The FDA's warning letters are a reminder that quality is not a given. It is a choice. And for researchers, it is a choice that determines whether their work advances the field or just adds noise.
Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
Common questions
Why did the FDA issue warning letters to tirzepatide compounders?
The FDA cited sterility lapses, use of non-pharmaceutical-grade ingredients, and mass production of tirzepatide after it was removed from the drug shortage list. Compounding pharmacies must follow strict quality standards, and the agency found many were not.
How does this affect research with other peptides like AOD-9604 or MOTS-c?
These peptides are often sourced from the same compounding pharmacies. The quality failures seen with tirzepatide, such as contamination or incorrect potency, can apply to any peptide made in a substandard facility. Researchers should verify quality independently.
Is retatrutide legally available for research from compounding pharmacies?
No. Retatrutide is an investigational drug not yet approved by the FDA. It cannot be legally compounded or sold for research use. Purchasing it from unregulated sources carries legal and scientific risks.
What steps can researchers take to ensure peptide quality?
Request a certificate of analysis from an independent lab, use pharmacopeial reference standards when possible, and document the entire supply chain. Budgeting for higher-quality sources can prevent data loss from failed experiments.
This is an editorial discussion of published research. It is not a treatment plan.